Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C cure associated with significant improvement in liver stiffness in people with HIV and HCV co-infection

A successful response to hepatitis C virus (HCV) therapy is associated with a significant improvement in liver stiffness among people with HIV and HCV co-infection, French investigators report

Published
17 August 2015
By
Michael Carter
People with hepatitis B can safely use Truvada PrEP for HIV prevention

People with hepatitis B virus (HBV) infection did not experience liver inflammation 'flares' or other adverse events when they used or stopped using Truvada for HIV pre-exposure prophylaxis

Published
14 August 2015
By
Liz Highleyman
How the Heroin Crisis Ushered in a Hepatitis C Epidemic

Meanwhile, high prices and stringent requirements from insurers and Big Pharma are limiting access to effective treatment.

Published
12 August 2015
From
Boston magazine
Cirrhosis and decompensation are common among people with chronic hepatitis C

More than one-quarter of people with chronic hepatitis C at Kaiser-Permanente developed liver cirrhosis over 12 years and 40% of these experienced decompensation – higher rates than

Published
11 August 2015
By
Liz Highleyman
Improving access to, and completion of, hepatitis C treatment

Treating hepatitis C infection is an effective and cost-effective way to substantially reduce prevalence, especially in areas where it is high. Compliance with the new treatment is easier and can be further improved by well-planned support for patients. .

Published
04 August 2015
From
Public Health England
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
04 August 2015
From
Intellectual Property Watch
Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme

Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and

Published
03 August 2015
By
Liz Highleyman
NICE issues appraisal consultation documents for three new hepatitis C therapies

The National Institute for Clinical Excellence (NICE) has today issued appraisal consultation documents for three new hepatitis C therapies; ledipasvir-sofosbuvir (Harvoni), daclatasvir (Daklinza, and ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).

Published
30 July 2015
From
Hepatitis C Trust
Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge

Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.

Published
30 July 2015
From
Bloomberg
Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies

Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in

Published
29 July 2015
By
Liz Highleyman

Filter by country